- Home
- NNAVW vs GALT Comparison
NNAVW vs GALT Comparison
Compare NNAVW & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$7.15
HOLD
Current Price
$4.08
Company Overview
Basic Information| Metric | NNAVW | GALT |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | 96 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 261.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NNAVW | GALT |
|---|---|---|
| Price | $7.15 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 53.1K | ★ 803.2K |
| Earning Date | 03-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,963,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.44 | N/A |
| 52 Week Low | $4.47 | $0.94 |
| 52 Week High | $4.70 | $7.13 |
Technical Indicators
Market Signals| Indicator | NNAVW | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 61.48 | 35.60 |
| Support Level | $7.26 | $3.90 |
| Resistance Level | $7.65 | $4.19 |
| Average True Range (ATR) | 0.41 | 0.60 |
| MACD | -0.04 | -0.22 |
| Stochastic Oscillator | 47.37 | 16.25 |
Price Performance
Historical Comparison NNAVW
GALT
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.